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Abstract 
Background: Therapeutic interchange policies in hospitals are useful in dealing with antimicrobial 
shortages and minimising resistance rates. The extent of antimicrobial shortages and availability of 
therapeutic interchange policies is unknown among public sector hospitals in South Africa. This 
study aimed to ascertain the extent and rationale for dealing with antimicrobial shortages and 
describe policies or guidelines and the role of pharmacists in the process. Methods: A quantitative 
and descriptive study was conducted with a target population of 403 public sector hospitals. Data 
were collected from hospital pharmacists using an electronic questionnaire via SurveyMonkeyTM. 
Results: The response rate was 33.5% and most (83.3%) hospitals had experienced shortages in 
the previous six months. Antimicrobials commonly reported as out of stock included cloxacillin 
(54.3%), benzathine benzylpenicillin (54.2%), and erythromycin (39.6%). Reasons for shortages 
included pharmaceutical companies with supply constraints (85.3%) and an inefficient supply 
system. Only 42.4% had therapeutic interchange policies, and 88.9% contacted the prescriber when 
there for substitution. Conclusions: Antimicrobial shortages are prevalent in South African public 
sector hospitals with the most affected being penicillins and cephalosporins. Therapeutic 
interchange policies are not available at most hospitals. Effective strategies are required to improve 
communication between pharmacists and prescribers to ensure that safe, appropriate, and 
therapeutically equivalent alternatives are available.  
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1. Background 
 
Sub-Saharan countries including South Africa have the highest burden of infectious diseases 
worldwide, enhanced by high prevalence rates of HIV, malaria, and tuberculosis [1–3], with 
antimicrobials crucial to reduce the burden of communicable diseases [4]. On one hand, there are 
concerns regarding the inappropriate use of antibiotics leading to increasing rates of antimicrobial 
resistance (AMR) limiting therapeutic options, which have resulted in antimicrobial stewardship 
programmes (ASPs) across countries acknowledging the challenges [5–8]. However, shortages of 
antimicrobials are also a challenge in Africa [9–11], potentially resulting in the use of antibiotics that 
place patients at a greater risk of Clostridium difficile infections as well as increased AMR [12,13]. 
 
The medicine shortage situation in South Africa is also a concern receiving media attention [14–16]. 
As a result, national monitoring programmes have been put in place in South Africa with the support 
of the National Department of Health (NDoH) surrounding improved supply management as well as 
the ‘Stop Stockouts’ initiative [17,18]. Despite these initiatives, shortages are still being experienced 
in some provinces in South Africa [16,18,19]. Shortages of antimicrobials are regarded as a public 
health emergency due to the necessity to expedite treatment in the case of an infection and 
because escalating AMR rates limit therapeutic options for many pathogens [20,21].  
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Where shortages of antimicrobials exist, therapeutic interchange policies can potentially help 
ensure that substitution is not haphazard or inappropriate [22]. Pharmacists can play a crucial role 
in the development and implementation of therapeutic interchange policies in hospitals combined 
with other key stakeholder groups, building on activities within Pharmacy and Therapeutic 
Committees (PTCs) as well as ASPs [8,23,24]. Whilst the effective functioning of PTCs is improving 
in South Africa and ASPs are evolving [23,24], there are concerns regarding the extent of 
therapeutic interchange policies among public hospitals in South Africa, especially regarding 
antimicrobials. The NDoH published a policy in 2017 to provide guidance for the placement of 
medicines in classes to support therapeutic interchange programmes where pertinent [25]. 
However, the policy only provides guidelines on required procedures when switching a patient from 
one medicine to another within the same therapeutic class, but not on therapeutic interchanges 
where this is not possible such as antimicrobials. As a result, there is a need to build on this 
initiative. 
 
Consequently, this study sought to identify and describe the current therapeutic interchange policies 
in the event of drug shortages among public sector hospitals in South Africa following the NDoH 
initiative. Antimicrobials were chosen in light of the extent of infectious diseases in sub-Saharan 
Africa, with public sector hospitals chosen as they offer health services to approximately 80% of the 
population in South Africa [17]. The findings can be used to guide future policies in South Africa. 
 
2. Materials and Methods 
We used a descriptive survey design and a quantitative research approach. All public sector 
hospitals including district, regional, and tertiary/academic hospitals (n = 403) in the nine provinces 
of South Africa were targeted for participation. One pharmacist from each hospital, in most 
instances the ‘Drug Controller’, ‘Procurement Pharmacist’, or ‘Pharmacy Manager’, were 
purposively selected to complete the questionnaire. In hospitals where none of these were 
available, a qualified pharmacist or community service pharmacist was requested to participate. 
Data were collected from March to July 2018. The survey was conducted using a 23 item electronic 
questionnaire administered via SurveyMonkey™. A questionnaire link was sent via email or fax to 
pharmacists who agreed to take part with anonymous completion. The questionnaire was based on 
the published literature [11,22,26–29] and followed by an expert review. It was divided into three 
sections: demographics, antimicrobial shortages, and therapeutic interchange. The questionnaire 
also included information on current PTC and ASP activities in the hospitals. 
 
Data were exported from SurveyMonkey™ to Microsoft Office Excel™ and cleaned prior to analysis 
using the Statistical Package for the Social Sciences (SPSS) version 25. Open-ended responses 
were typed into MS Excel™, and relevant categories were created to allow for the counting of 
responses. Descriptive statistics were used to summarise data using means with standard deviation 
(SD) and frequency counts with percentages. Antibiotics were classified by ATC class [30]. All 
analyses were conducted at a 95% confidence interval. 
 
Ethical clearance for the study was granted by the Sefako Makgatho University Research Ethics 
Committee (SMUREC/P/269/2017:PG), and permission was obtained from the NDoH. 
 
3. Results 
 
3.1. Response Rate and Demographic Details 
Of the 403 hospitals, approval to conduct the study was received for 346 hospitals (Table 1). Of 
these 346 hospitals, 81 facilities could not be reached using email addresses and 11 declined to 
participate. A total of 85 responses were finally received, giving a response rate of 33.5% (Table 1).  
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Table 1. Response rate and study population per province. 
Province 
Targe
t 
Popu
lation 
(n = 
403) 
Excluded from Target Population (n= 149) Study Population (n = 254) 
No 
Approva
l 
Respons
e 
Approva
l Denied 
Could not 
be 
Reached 
for an 
Email 
Address 
Declined 
Participation/ 
no 
Pharmacist/ 
no Email or 
Fax 
Email 
Delivere
d 
Non- 
Response 
Response
s Per 
province 
(%) 
Eastern Cape 90 0 0 28 3 59 41 18 (21.2%) 
Free State 34 0 1 17 2 14 8 6 (7.1%) 
Gauteng 36 26 0 0 0 10 2 8 (9.4%) 
Kwa-Zulu Natal 77 0 0 7 0 70 57 13 (15.3%) 
Limpopo 40 0 0 4 0 36 28 8 (9.4%) 
Mpumalanga 33 0 0 11 1 21 17 4 (4.7%) 
Northern Cape 19 0 0 1 3 15 2 13 (15.3%) 
North West 20 0 0 1 1 18 10 8 (9.4%) 
Western Cape 54 20 10 12 1 11 4 7 (8.2%) 
Total number 
(%) 
403 
46 
(11.4%) 
11 
(2.7%) 
81 (20.1%) 11 (2.7%) 254  
169 
(66.5%) 
85 (33.5%) 
 
More than half of the respondents were female (63.5%), with a mean age of 38 years (SD: 9.8) 
(Table 2). The mean number of years in practice was 9.3 years (SD: 7.42), with 62.2% having less 
than 10-years of experience. Almost half (48.2%) were pharmacy managers, with most working at 
district hospitals (Table 2). 
 
Table 2. Demographic characteristics of respondents (n = 85) 
 
Respondents’ Characteristics  
Respondents; n 
(%) 
Gender 
Male 31 (36.5%) 
Female 54 (63.5%) 
Age (years) 
20–30 19 (24.1%) 
˃30–40 28 (35.4%) 
˃40–50 20 (25.3%) 
˃50–65 12 (15.2%) 
Years of practice in the public 
sector 
≤10 51 (62.2%) 
˃10–20 24 (29.3%) 
˃20–30 5 (6.1%) 
˃30 2 (2.4%) 
Designation 
Pharmacy manager 41 (48.2%) 
Pharmacist (completed community service; no 
specific designation) 
19 (22.4%) 
Procurement Pharmacist 13 (15.3%) 
Drug controller 10 (11.8%) 
Clinical Pharmacist 4 (4.7%) 
Community Service Pharmacist 4 (4.7%) 
Production Pharmacist 2 (2.4%) 
Clinical supervisor 1 (1.2%) 
Sub-district Pharmacist 1 (1.2%) 
Level of care 
District hospital 43 (51.8%) 
Regional hospital 17 (20.5%) 
Tertiary hospital 11 (13.3%) 
Specialised hospital 10 (12.1%) 
Central hospital 3 (3.6%) 
 
3.2. Antimicrobial Shortages 
The majority of respondents (83.3%) indicated they had experienced antimicrobial shortages at their 
institutions in the previous six months. Most shortages were for antibiotics, particularly penicillins, 
with a limited number in the antiviral (acyclovir) and antifungal (amphoteracin B, clotrimazole) 
classes (Table 3). Most of the shortages exceeded 40 days. 
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Table 3. Antimicrobial shortages by ATC classification 
 
Antimicrobial 
Class 
ATC 
Classificati
on 
Antimicrobial 
Number of 
Responde
nts a 
Total Number 
(%) Who 
Reported 
Antimicrobial 
as Unavailable 
Average 
Duration 
of 
Shortages 
(days) 
Penicillins 
J01CF02 Cloxacillin 70 38 (54.3%) 5 to >40 
J01CE08 Benzathine Benzylpenicillin 72 39 (54.2%) 5 to >40 
J01CE02 Phenoxymethylpenicillin IV 58 28 (48.3%) 21 to >40 
J01CE02 Phenoxymethylpenicillin oral 71 31 (43.7%) 5 to >40 
J01CE01 Benzyl Penicillin 72 24 (33.3%) 5 to >40 
J01CE09 Procaine Penicillin 55 14 (25.5%) 21 to >40 
J01CA01 Ampicillin IV 72 15 (20.8%) 5 to >40 
B-lactam inhibitor 
combinations 
J01CR02 
Amoxicillin/Clavulanic Acid 
IV 
71 21 (29.6%) 5 to >40 
J01CR05 Piperacillin/Tazobactam 61 16 (26.2%) 5 to 40 
Macrolides 
J01FA01 Erythromycin 53 21 (39.6%) 5 to >40 
J01FA10 Azithromycin IV 59 11 (18.6%) 11 to 40 
Cephalosporins 
J01DD04 Ceftriaxone 71 27 (38.0%) 5 to >40 
J01DE01 Cefepime 53 14 (26.4%) 5 to >40 
Aminoglycosides J01GB03 Gentamicin 67 19 (28.4%) 5 to >40 
Imidazole antifungal D01AC01 Clotrimazole cream 71 20 (28.2%) 5 to >40 
Glycopeptides 
J01XA01 Vancomycin Oral 40 11 (27.5%) >40 
J01XA01 Vancomycin IV 62 13 (21.0%) 11 to 40 
Synthetic 
nucleoside 
analogue antiviral 
D06BB03 Aciclovir IV 58 14 (24.1%) 5 to >40  
Tetraene polyene 
antifungal 
D01AA02 Natamycin 43 8 (18.6%) >40 
Polyene antifungal J02AA01 Amphoteracin B 72 13 (18.1%) 5 to >40 
 NB: a Total number of respondents who indicated the antimicrobial as either available or not available. 
3.3. Reasons for Antimicrobial Shortages  
The majority of respondents (85.3%) stated that supply problems with pharmaceutical companies 
were the main contributor to shortages (Table 4). The impact included dispensing later generation 
(84.4%) and more expensive alternatives (64.9%). The procedures for reporting medicine shortages 
included sending weekly reports to the central/provincial office or district pharmacist (Table 4). 
Table 4. Reasons for, impact of, and procedures for reporting antimicrobial shortages. 
Reasons for Antimicrobial 
Shortages a 
Hospital Level of Care 
Total (%) 
(n = 75) 
District 
(n = 37) 
Regional 
(n = 15) 
Tertiary 
(n = 10) 
Central 
(n = 3) 
Specialised 
(n =1 0) 
Pharmaceutical companies 
with supply or capacity 
problems 
33 
(51.6%) 
11 
(17.2%) 
7 
(10.9%) 
3 (4.7%) 10 (15.6%) 
64 
(85.3%) 
Inefficient supply system from 
the depot to the facility 
31 
(56.4%) 
10 
(11.1%) 
8 
(14.5%) 
1 (1.8%) 5 (9.1%) 
55 
(73.3%) 
Poor stock control systems 9 (50.0%) 5 (27.8%) 
2 
(11.1%) 
0 (0.0%) 2 (11.1%) 
18 
(24.0%) 
Shortage of funds/ resources 9 (50.0%) 5 (27.8%) 
2 
(11.1%) 
1 (5.6%) 1 (5.6%) 
18 
(24.0%) 
Wastage of medicines 5 (35.7%) 3 (21.4%) 
3 
(21.4%) 
1 (7.1%) 2 (14.3%) 
14 
(18.7%) 
Increase in the number of 
patients relying on the facility 
for medication 
7 (50.0%) 4 (28.6%) 
2 
(14.3%) 
0 (0.0%) 1 (7.1%) 
14 
(18.7%) 
Lack of reliable information on 
medicine needs and usage 
4 (33.3%) 4 (33.3%) 
4 
(33.3%) 
0 (0.0%) 0 (0.0%) 
12 
(16.0%) 
Unclear lines of accountability 5 (71.4%) 0 (0.0%) 
1 
(14.3%) 
0 (0.0%) 1 (14.3%) 7 (9.3%) 
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Poor ordering practices by 
pharmacists or nurses 
4 (80.0%) 0 (0.0%) 
1 
(20.0%) 
0 (0.0%) 0 (0.0%) 5 (6.7%) 
Protest action resulting in shut 
down of depot 
4 (80.0%) 1 (20.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 5 (6.7%) 
Lack of storage facilities for 
medicines 
3 
(100.0%) 
0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 3 (4.0%) 
Unapproved tenders/ changes 
to tender 
0 (0.0%) 1 (50.0%) 
1 
(50.0%) 
0 (0.0%) 0 (0.0%) 2 (2.7%) 
Need to motivate for drugs 0 (0.0%) 
1 
(100.0%) 
0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (1.3%) 
Requested quantities too small 
for depot to supply 
0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (100.0%) 1 (1.3%) 
Impact of antimicrobial 
shortages a 
District 
(n = 37) 
Regional 
(n = 16) 
Tertiary 
(n = 11) 
Central 
(n = 3) 
Specialised 
(n = 10) 
Total (%) 
(n = 77) 
Dispensed second/third/fourth 
generation antimicrobials 
35 
(53.8%) 
14 
(21.5%) 
10 
(15.4%) 
2 (3.1%) 6 (9.2%) 
65 
(84.4%) 
Dispensed more expensive 
alternatives 
26 
(52.0%) 
12 
(24.0%) 
9 
(18.0%) 
1 (2.0%) 2 (4.0%) 
50 
(64.9%) 
Turned patient away with no 
medication 
14 
(63.6%) 
3 (13.6%) 2 (9.1%) 1 (4.5%) 2 (9.1%) 
22 
(28.6%) 
Referred patient to a private 
institution 
10 
(55.6%) 
3 (16.7%) 
4 
(22.2%) 
0 (0.0%) 1 (5.6%) 
18 
(23.4%) 
Procedure for reporting 
shortages a 
District 
(n = 35) 
Regional 
(n = 17) 
Tertiary 
(n = 8) 
Central 
(n = 1) 
Specialised 
(n = 7) 
Total (%) 
(n = 68) 
Weekly reports to central/ 
provincial office or district 
pharmacist 
14 
(53.8%) 
5 (19.2%) 
3 
(11.5%) 
0 (0.0%) 4 (15.4%) 
26 
(38.2%) 
Report to PTC 6 (40.0%) 4 (26.7%) 
3 
(20.0%) 
0 (0.0%) 2 (13.3%) 
15 
(22.1%) 
Update on inventory 
management system/ out of 
stock book 
8 (61.5%) 4 (30.8%) 1 (7.7%) 0 (0.0%) 0 (0.0%) 
13 
(19.1%) 
Notify prescribers via 
telephone, email, meetings, 
SOPs or notices  
8 (61.5%) 2 (15.4%) 
2 
(15.4%) 
0 (0.0%) 1 (7.7%) 
13 
(19.1%) 
Notify pharmacy management 4 (33.3%) 4 (33.3%) 
3 
(25.0%) 
1 (8.3%) 0 (0.0%) 
12 
(17.6%) 
Notify the depot 5 (62.5%) 2 (25.0%) 
1 
(12.5%) 
0 (0.0%) 0 (0.0%) 8 (11.8%) 
Report to CEO and PTC 3 (42.9%) 1 (14.3%) 
1 
(14.3%) 
0 (0.0%) 2 (28.6%) 7 (10.3%) 
Not available 
3 
(100.0%) 
0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 3 (4.4%) 
NB: a More than one response option provided. CEO: Chief Executive Officer; PTC: Pharmacy and 
Therapeutics Committee; SOP: Standard Operating Procedure. 
A considerable number of facilities had active PTCs (86.9%) and Antimicrobial Stewardship 
Committees (AMSCs) (70.2%). Most respondents were members of PTCs (77.4%) and AMSCs 
(51.2%).  
 
3.4. Therapeutic Interchange Policies 
Less than half (42.4%) of respondents stated they had therapeutic interchange policies in place in 
their hospitals, of whom 30.2% reported that these were documented (Table 5). Pre-consultation 
with the prescriber before substitution was a requirement in 95.2% of the facilities. The extent of 
policies, their development, actions taken by pharmacist, and substitution procedures followed in 
the absence of policies are documented in Table 5. 
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Table 5. Therapeutic interchange process by hospital level of care 
 
Policy Hospital Level of Care 
Therapeutic interchange policy 
description 
District 
(n = 18) 
Regional 
(n = 11) 
Tertiary 
(n = 5) 
Central 
(n = 1) 
Specialised 
(n = 4) 
Total (%)  
(n = 39) 
Memo from National Department of 
Health 
6 (46.2%) 5 (38.5%) 1 (7.7%) 1 (7.7%) 0 (0.0%) 13 (33.3%) 
SOP/guidelines from PTCs 7 (77.8%) 2 (22.2%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 9 (23.1%) 
Not available 1 (14.3%) 1 (14.3%) 3 (42.9 0 (0.0%) 2 (28.6%) 7 (17.9%) 
Hospital notice with 
alternatives/supplementary list 
2 (50.0%) 2 (50.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 4 (10.3%) 
Internal arrangement between 
pharmacists and prescribers 
1 (25.0%) 1 (25.0%) 0 (0.0%) 0 (0.0%) 2 (50.0%) 4 (10.3%) 
Alternatives from the depot 1 (50.0%) 0 (0.0%) 
1 
(50.0%) 
0 (0.0%) 0 (0.0%) 2 (5.1%) 
Health personnel responsible for 
development of therapeutic 
interchange policies a 
District 
(n = 39) 
Regional 
(n = 17) 
Tertiary 
(n = 11) 
Provincial 
(n = 3) 
Specialised 
(n = 10) 
Total (%) 
(n = 82) 
Pharmacy and Therapeutics 
Committee 
25 (61.0%) 6 (14.6%) 3 (7.3%) 3 (7.3%) 4 (9.8%) 41 (50.0%) 
Pharmacist 12 (46.2%) 5 (19.2%) 
5 
(19.2%) 
2 (7.7%) 2 (7.7%) 26 (31.7%) 
Prescribers 9 (45.0%) 3 (15.0%) 
3 
(15.0%) 
1 (5.0%) 4 (20.0%) 20 (24.4%) 
National Department of Health 1 (33.3%) 2 (66.7%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 3 (3.7%) 
Microbiologist 0 (0.0%) 2 (100.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (2.4%) 
Operational manager (registered 
nurses) 
1 (100.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (1.2%) 
Not applicable 10 (45.5%) 6 (27.3%) 
4 
(18.2%) 
0 (0.0%) 2 (9.1%) 22 (26.8%) 
Actions taken by the pharmacist 
during the therapeutic interchange 
process a   
District 
(n = 41) 
Regional 
(n = 17) 
Tertiary 
(n = 11) 
Provincial 
(n = 3) 
Specialised 
(n = 10) 
Total (%) 
(n = 82) 
Communicate with other health 
professionals regarding any ongoing 
medicine shortages and available 
substitutions 
39 (50.6%) 16 (20.8%) 
10 
(13.0%) 
2 (2.6%) 10 (13.0%) 77 (93.9%) 
Keep a record of the interchange 25 (49.0%) 10 (19.6%) 
8 
(15.7%) 
2 (3.9%) 6 (11.8%) 51 (62.2%) 
Patient counselling 28 (68.3%) 4 (9.8%) 
6 
(14.6%) 
1 (2.4%) 2 (4.8%) 41 (50.0%) 
None 2 (100.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (2.4%) 
Provide prescribers with information 
on new therapeutic equivalent and 
correct dosages 
1 (100.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (1.2%) 
Antimicrobial substitution 
procedures, followed by 
pharmacists, in the absence of 
therapeutic interchange policies a  
District 
(n = 42) 
Regional 
(n = 17) 
Tertiary 
(n = 11) 
Central 
(n = 2) 
Specialised 
(n=9) 
Total (%) 
(n=81) 
Call to notify the prescriber, avail the 
options and they choose/ endorse 
change before dispensing alternative 
38 (52.8%) 14 (19.4%) 
10 
(13.9%) 
3 (4.2%) 7 (9.7%) 72 (88.9%) 
Send a written memo to the 
prescribers supplying the available 
options 
19 (40.4%) 14 (29.8%) 
7 
(14.9%) 
3 (6.4%) 4 (8.5%) 47 (58.0%) 
Send the patient back to the 
prescriber 
10 (45.5%) 7 (31.8%) 2 (9.1%) 1 (4.5%) 2 (9.1%) 22 (27.2%) 
Consult pharmacists at tertiary level 
for alternatives 
1 (100.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (1.2%) 
Borrow or buy out from other 
institutions 
1 (100.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (1.2%) 
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Urgent meeting by Rational 
Medicines Use Committee to discuss 
way forward 
1 (100.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (1.2%) 
 NB: a More than one response option provided. 
3.5. Role of the Pharmacist in Therapeutic Interchange 
More than a third of the respondents (37.1%) said the pharmacists should communicate with 
prescribers regarding suitable therapeutic options when there are shortages as well as facilitate the 
development of therapeutic interchange policies (22.9%) to improve subsequent care (Table 6). 
 
Table 6. Perceived role of the pharmacist in the therapeutic interchange process. 
 
Role of the Pharmacist 
Hospital Level of Care Total 
(%) 
(n = 70) 
District 
(n = 36) 
Regional 
(n = 16) 
Tertiary 
(n = 9) 
Central 
(n = 1) 
Specialised 
(n = 8) 
Share information and communicate 
with prescribers on rational medicine 
use and available therapeutic 
options 
12 
(46.2%) 
6 
(23.1%) 
4 
(15.4%) 
1 
(3.8%) 
3  
(11.5%) 
26 
(37.1%) 
Facilitate therapeutic interchange 
policy development and/or selection 
of therapeutic alternatives in the 
PTC 
11 
(68.8%) 
2 
(12.5%) 
2 
(12.5%) 
0 
(0.0%) 
1  
(6.3%) 
16 
(22.9%) 
Work as part of a team with 
clinicians to provide the best 
therapeutic alternatives for the 
patient 
6  
(40.0%) 
4 
(26.7%) 
2 
(13.3%) 
0 
(0.0%) 
3  
(20.0%) 
15 
(21.4%) 
Participate in research with other 
health care professionals to make 
informed medicine choices 
2  
(33.3%) 
2 
(33.3%) 
1 
(16.7%) 
0 
(0.0%) 
1  
(16.7%) 
6  
(8.6%) 
Interchange without consulting the 
prescriber to reduce patient waiting 
times if all the patient information is 
available 
2  
(50.0%) 
2 
(50.0%) 
0  
(0.0%) 
0 
(0.0%) 
0  
(0.0%) 
4  
(5.7%) 
Educate and counsel patients on 
changes to their treatment 
3 
(100.0%) 
0  
(0.0%) 
0  
(0.0%) 
0 
(0.0%) 
0  
(0.0%) 
3  
(4.3%) 
NB: PTC: Pharmacy and Therapeutics Committee. 
4. Discussion 
 
We believe this is the first comprehensive study among public sector hospitals in South Africa to 
review the current situation regarding therapeutic interchange policies following NDoH guidance 
[25]. The response rate of 33.5%, despite sending up to 12 reminders, was similar to one study in 
the US (40%) [31]; however, it was higher than studies in Europe and another study in the US with 
response rates of 22% and 13%, respectively [29,32]. Pharmacy managers provided the highest 
number of responses (Table 2), similar to a study conducted in the US [33].  
 
The majority of participating hospitals had experienced antimicrobial shortages in the preceding six 
months, similar to studies conducted in Australia, Europe, and the US [32,34]. Shortages were 
either reported to the pharmacy manager, the PTC, hospital management, or the provincial office by 
the pharmacists, similar to the findings in a US survey [31]. It is important that shortages are 
reported to the relevant authorities and immediately communicated to prescribers so that pertinent 
strategies can be urgently identified and implemented. 
 
The majority of shortages reported were for penicillins, followed by cephalosporins (Table 3), similar 
to findings in the US, Europe, and Australia [10,11,32,34]. Most of the shortages lasted more than 
40 days. This is a concern, although shortages between one week and over a year have been seen 
in Europe and the US [11,32]. Pharmaceutical companies with supply or capacity problems, an 
inefficient supply system, poor stock control and financial resources were the main reasons for 
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shortages (Table 4).  However, new initiatives have recently been introduced in South Africa to help 
improve stock control, and we will be researching their impact in future studies [17]. 
 
Most pharmacists reported that they had resorted to dispensing later generation antimicrobials or 
more expensive alternatives when faced with shortages, similar to studies in Europe and Australia 
[32,34]. This though may potentially hinder AMS efforts as shortages of one antimicrobial can result 
in shortages of others used for substitution, potentially negatively impacting patient outcomes [35].  
 
Encouragingly, the majority of the respondents said that their hospitals had active PTCs and 
AMSCs. This is welcomed, especially as one of the aims and objectives of the South African 
National Drug Policy is to establish and strengthen PTCs in all hospitals [23,24,36]. However, of 
concern was that less than half of the respondents (42.4%) stated their hospitals had therapeutic 
interchange policies. Of these, only nine had policies or substitution guidelines from their 
institutional PTCs. This is consistent though with a recent survey conducted among public sector 
hospitals in South Africa that found that the development and implementation of guidelines other 
than the formulary is not a primary function of hospital PTCs [23]. In addition, only 33% of 
participants referred to the NDoH notice to develop their therapeutic interchange policies. This 
needs to be addressed as it is difficult to adhere to and revise guidelines that are not documented 
and actively communicated.  
 
Half of the respondents stated that therapeutic interchange policies were the responsibility of PTCs, 
with PTCs generally considered the most ideal setting for such programmes, which is encouraging 
as they can ensure that any guidelines are based on scientific evidence and any national Essential 
Medicine List [17,37–39].  Several actions were reported as part of the pharmacist’s practice during 
substitution (Table 5) including communication with other health professionals and providing 
information on available alternatives. This is also important as decisions should be made in 
collaboration with all key stakeholders [35]. Encouragingly, very few respondents stated they 
substituted without consulting the prescriber, with 92.5% stating that pre-consultation with the 
prescriber was a requirement before substitution in their hospital. This is important for building trust 
among teams. The opposite was observed in the US where 67% of institutions performed automatic 
substitutions preapproved by PTCs [31]. More than a quarter of respondents sent the patient back 
to the prescriber when a prescribed medicine was unavailable, implying that shortages were not 
always communicated in a timely manner. This needs to be addressed as it is important that 
pharmacists actively communicate with prescribers and help jointly develop therapeutic interchange 
policies to optimize patient care and minimize patient inconvenience [22,40]. 
 
Encouragingly, keeping a record of the interchange was undertaken by more than half of the 
respondents. Additionally, it was  encouraging that respondents emphasised the importance of 
communication with prescribers and active participation in research related to substitution decisions 
as well as facilitation of therapeutic interchange policy development (Table 6) in going forward. We 
will be building on this in future studies. Finally, some pharmacists have highlighted the importance 
of effective communication channels between the National/Provincial Department of Health and 
health facilities, which is consistent with the WHO’s recommendation to scale up systems at a 
national level that collect and monitor data on medicine availability for better evidence-based policy 
making [41]. 
 
The study had several limitations. We acknowledge there was a relatively low response rate, more 
than half of the respondents had less than 10-years of experience, and the responses were self-
reported. It is also likely that not all shortages were accounted for due to recall bias. There also 
appeared to be differences in the interpretation of therapeutic interchange policies among the 
pharmacists taking part. Despite these limitations, we believe that the study was robust, providing 
an insight into the current status of antimicrobial shortages and interchange policies among public 
sector hospitals in South Africa.  
 
5. Conclusions and Recommendations 
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From our findings, it is evident that most South African public sector hospitals experience 
antimicrobial shortages, particularly for penicillins and cephalosporins. These shortages may last in 
excess of 40 days, which can affect service delivery, AMS efforts, and patient outcomes. Of 
concern is that the practice of therapeutic interchange is currently not that common in South Africa 
and not entirely understood by pharmacists working in public sector hospitals. Efforts should be 
made to train PTC members on how to develop evidence-based policies to manage medicine 
shortages in their institutions, with pharmacists playing a key role based on their training. There 
should also be increased communication with depots and ordering early considering depot lead 
times. 
 
We also believe that based on our findings, clear processes for the effective communication of 
anticipated and ongoing shortages of medicines including antimicrobials should be established 
among all public sector hospitals. These hospitals should design and implement measures to 
ameliorate weaknesses in the inventory control process as well as minimise disruptions in medicine 
supply, building on current initiatives in South Africa. These measures should prioritise antimicrobial 
preservation given concerns with rising AMR rates in South Africa.  
 
Furthermore, therapeutic interchange policies should be considered for implementation at various 
levels of care as they take into consideration the spectrum of activity, cost, and associated adverse 
drug reactions of different antimicrobials, which can be part of ASP programmes. We hope our 
findings are of interest to other low to medium income countries experiencing challenges with 
medicine shortages, especially antimicrobials in hospitals. 
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